相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.
Douglas W. Blayney et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies
James R. Tonra et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses
Abhishek S. Kashyap et al.
CELL REPORTS (2019)
Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
Jihyoun Lee et al.
ANNALS OF SURGICAL TREATMENT AND RESEARCH (2018)
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Aly-Khan A. Lalani et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score
Theis Aagaard et al.
JNCI CANCER SPECTRUM (2018)
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
Michael R. Cassidy et al.
EBIOMEDICINE (2017)
Summary scores captured changes in subjects' QoL as measured by the multiple scales of the EORTC QLQ-C30
Rachel Phillips et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2015)
Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value
Michaela A. Dinan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial
Norikazu Masuda et al.
SUPPORTIVE CARE IN CANCER (2015)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia
Maureen J. Aarts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets
Ben van Hout et al.
VALUE IN HEALTH (2012)
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.
Miguel Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies
Howard A. Burris et al.
JOURNAL OF ONCOLOGY PRACTICE (2010)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer
FA Holmes et al.
ANNALS OF ONCOLOGY (2002)
Taxane/anthracycline combinations: Setting a new standard in breast cancer?
JM Nabholtz et al.
ONCOLOGIST (2001)
分享论文
